64x Bio
64x Bio, based in San Francisco, specializes in enhancing mammalian cell line discovery for viral vector production, serving the pharmaceutical and biotechnology industries.
Company Overview of 64x Bio
64x Bio, previously known as 64-X and 64-x, is a healthcare company based in San Francisco, CA, USA. Established in 2020, the company focuses on building a platform to accelerate and scale mammalian cell line discovery. The company operates within the healthcare industry, particularly in the industrial bio sub-sector, and serves regions within the United States and America/Canada.
64x Bio Services
64x Bio specializes in developing highly optimized cell lines for the manufacturing of viral vectors utilized in cell and gene therapies. The core service of the company revolves around a novel high throughput discovery and screening platform, which is integrated with computational design. This platform aims to enhance the efficiency of viral vector production and reduce overall manufacturing costs, providing significant value to pharmaceutical and biotechnology companies.
64x Bio's High Throughput Discovery and Screening Platform
64x Bio employs a cutting-edge high throughput discovery and screening platform integrated with computational design. This technology significantly speeds up the process of mammalian cell line discovery and optimization. By utilizing this platform, 64x Bio can generate purpose-built genetically engineered cell lines, thereby improving the efficacy and reducing the production costs of viral vectors used in cell and gene therapy manufacturing.
Founding and Team of 64x Bio
64x Bio was founded in 2020 and is part of the Y-Combinator S18 batch. The company has a dedicated team of 25 professionals based in San Francisco, CA. Through their combined expertise, the team at 64x Bio is pushing forward the boundaries of cell line development and viral vector production, contributing to advancements in cell and gene therapies.
Regions and Operational Scope of 64x Bio
64x Bio primarily operates within the regions of the United States of America and America/Canada. The company provides its advanced cell line development services to pharmaceutical and biotechnology companies within these regions, helping to enhance their manufacturing processes for viral vectors used in revolutionary cell and gene therapies.